Posted on 19/03/2010 in Pharmaceutical Company Product News Roche has expressed confidence that its business model will allow it to further its objectives of growth and clinical advancement in the future.
The company has presented its first investor conference since its takeover of Genentech, stating the firm is now "uniquely positioned to deliver sustainable, long-term growth".
It highlighted its continuing progress on its potentially groundbreaking brain disease treatments RG1678 and ocrelizumab, both of which have demonstrated promising attributes in clinical trials.
Roche also underlined the fact that it has a number of cancer and metabolic disease treatments in ongoing or planned late-stage studies, with these expansions to its portfolio expected to underpin its future growth.
Severin Schwan, chief executive officer of Roche, said: "Our success derives from the diversity of approaches applied by our pharmaceuticals and diagnostics research and development centres, which offer outstanding scientific excellence and an unparalleled breadth and depth of expertise."
Last month, the company received Food and Drug Administration approval for its treatment Rituxan/MabThera to be used as a therapy for chronic lymphocytic leukaemia.Other news stories from 19/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
